160 related articles for article (PubMed ID: 9434452)
1. [Measures to meet the side effects of the orally administered antihyperglycemic drugs].
Ishii J; Inoue I
Nihon Rinsho; 1997 Nov; 55 Suppl():104-13. PubMed ID: 9434452
[No Abstract] [Full Text] [Related]
2. [Adverse effects of oral hypoglycemic agents].
Mori Y; Sekihara H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():325-31. PubMed ID: 12387013
[No Abstract] [Full Text] [Related]
3. [Oral hypoglycemic agents--overview].
Sakamoto N; Uno T
Nihon Rinsho; 1997 Nov; 55 Suppl():94-8. PubMed ID: 9434450
[No Abstract] [Full Text] [Related]
4. [Pitfalls in treatment with oral antidiabetic agents].
Perusicová J
Vnitr Lek; 1998 Jan; 44(1):30-5. PubMed ID: 9750481
[TBL] [Abstract][Full Text] [Related]
5. [Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM].
Kitaoka H
Nihon Rinsho; 1997 Nov; 55 Suppl():192-6. PubMed ID: 9434466
[No Abstract] [Full Text] [Related]
6. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Kitaoka H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035
[No Abstract] [Full Text] [Related]
7. [Complications in treatment with peroral antidiabetic preparations].
Shcherbak AV
Probl Endokrinol (Mosk); 1988; 34(3):46-54. PubMed ID: 3047731
[No Abstract] [Full Text] [Related]
8. Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose).
Alsheikh-Ali AA; Abourjaily HM; Karas RH
Am J Cardiol; 2002 Jun; 89(11):1308-10. PubMed ID: 12031736
[No Abstract] [Full Text] [Related]
9. [Selection of oral antidiabetic drugs].
Iwamoto Y
Nihon Rinsho; 2005 Feb; 63 Suppl 2():428-32. PubMed ID: 15779417
[No Abstract] [Full Text] [Related]
10. Treatment of type 2 diabetes mellitus.
Feinglos MN; Bethel MA
Med Clin North Am; 1998 Jul; 82(4):757-90. PubMed ID: 9706120
[TBL] [Abstract][Full Text] [Related]
11. [Current and future aspects of oral antidiabetic agents in type 2 diabetes].
Rybka J
Vnitr Lek; 2001 May; 47(5):285-90. PubMed ID: 11395869
[TBL] [Abstract][Full Text] [Related]
12. [Indication and side effect of alpha glucosidase inhibitor].
Katahira H; Ishida H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():399-408. PubMed ID: 12387025
[No Abstract] [Full Text] [Related]
13. Comparative tolerability profiles of oral antidiabetic agents.
Krentz AJ; Ferner RE; Bailey CJ
Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
[TBL] [Abstract][Full Text] [Related]
14. [Oral antidiabetics].
Bäbler M
Schweiz Rundsch Med Prax; 1972 Feb; 61(8):242-6. PubMed ID: 4659095
[No Abstract] [Full Text] [Related]
15. [Combination therapy with biguanides].
Sakura H
Nihon Rinsho; 2002 Oct; 60 Suppl 10():724-8. PubMed ID: 12430309
[No Abstract] [Full Text] [Related]
16. [Measures to meet the side effects of sulfonylurea (SU) in the treatment of type 2 diabetes].
Furukawa H; Ishida H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():357-61. PubMed ID: 12387018
[No Abstract] [Full Text] [Related]
17. [Adverse effects of alpha-glucosidase inhibitors].
Sakaguchi K; Kasuga M
Nihon Rinsho; 2007 Oct; 65 Suppl 8():183-7. PubMed ID: 18074536
[No Abstract] [Full Text] [Related]
18. [Indication and method of administration of oral antidiabetic agents].
Tasaka Y
Nihon Rinsho; 1997 Nov; 55 Suppl():99-103. PubMed ID: 9434451
[No Abstract] [Full Text] [Related]
19. Type 2 diabetes and oral antihyperglycemic drugs.
Mizuno CS; Chittiboyina AG; Kurtz TW; Pershadsingh HA; Avery MA
Curr Med Chem; 2008; 15(1):61-74. PubMed ID: 18220763
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors.
Bando Y; Ushiogi Y; Okafuji K; Toya D; Tanaka N; Fujisawa M
J Int Med Res; 1999; 27(2):53-64. PubMed ID: 10446691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
